Inventiva (NASDAQ:IVA) Cut to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Inventiva (NASDAQ: IVA) from a "hold" to a sell rating in a research note issued on Saturday.
• Despite the downgrade, the consensus among analysts remains a Buy with a consensus target price of $16.56 and individual targets ranging roughly from $12 to $24 from various firms.
• Shares opened at $5.26 (12‑month range $2.85–$7.98) and the company reported -$0.16 EPS for the quarter, with analysts forecasting -2.08 EPS for the year; institutional investors and hedge funds own about 19% of the stock.

Inventiva (NASDAQ:IVA - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

IVA has been the topic of several other reports. UBS Group started coverage on shares of Inventiva in a research note on Wednesday, January 7th. They set a "buy" rating and a $12.00 target price on the stock. Barclays started coverage on shares of Inventiva in a research note on Tuesday, January 27th. They issued an "overweight" rating and a $18.00 price target on the stock. Truist Financial started coverage on shares of Inventiva in a research note on Thursday, March 19th. They issued a "buy" rating and a $13.00 price target on the stock. Leerink Partners started coverage on shares of Inventiva in a research note on Monday, January 12th. They issued an "outperform" rating and a $12.00 price target on the stock. Finally, HC Wainwright set a $24.00 price target on shares of Inventiva and gave the stock a "buy" rating in a research note on Wednesday, January 28th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $16.56.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $5.26 on Friday. The company's fifty day moving average is $6.05 and its two-hundred day moving average is $5.37. Inventiva has a 12-month low of $2.85 and a 12-month high of $7.98.

Inventiva (NASDAQ:IVA - Get Free Report) last announced its earnings results on Saturday, February 14th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter. On average, equities research analysts forecast that Inventiva will post -2.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Inventiva

A number of hedge funds have recently modified their holdings of IVA. Creative Planning acquired a new position in shares of Inventiva in the second quarter worth $32,000. Virtu Financial LLC bought a new stake in Inventiva in the fourth quarter worth $60,000. XTX Topco Ltd bought a new stake in Inventiva in the fourth quarter worth $84,000. Cerity Partners LLC bought a new stake in Inventiva in the fourth quarter worth $93,000. Finally, NewEdge Advisors LLC bought a new stake in Inventiva in the third quarter worth $116,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.